MRK
Merck & Co., Inc. NYSE Listed Jan 13, 1978$112.30
Mkt Cap $277.3B
52w Low $73.31
75.2% of range
52w High $125.14
50d MA $116.93
200d MA $100.39
P/E (TTM)
15.4x
EV/EBITDA
11.8x
P/B
5.3x
Debt/Equity
1.0x
ROE
34.7%
P/FCF
21.4x
RSI (14)
—
ATR (14)
—
Beta
0.28
50d MA
$116.93
200d MA
$100.39
Avg Volume
10.9M
Merck & Co., Inc. operates as a healthcare company worldwide. It operates through two segments, Pharmaceutical and Animal Health. The Pharmaceutical segment offers human health pharmaceutical products in the areas of oncology, hospital acute care, immunology, neuroscience, virology, cardiovascular, and diabetes, as well as vaccine products, such as preventive pediatric, adolescent, and adult vaccines. The Animal Health segment discovers, develops, manufactures, and markets veterinary pharmaceuticals, vaccines, and health management solutions and services, as well as digitally connected identification, traceability, and monitoring products. It serves drug wholesalers and retailers, hospitals, and government agencies; managed health care providers, such as health maintenance organizations, pharmacy benefit managers, and other institutions; and physicians and physician distributors, veterinarians, and animal producers. The company has collaborations with AstraZeneca PLC; Bayer AG; Eisai Co., Ltd.; Ridgeback Biotherapeutics; and Gilead Sciences, Inc. to jointly develop and commercialize long-acting treatments in HIV. Merck & Co., Inc. was founded in 1891 and is headquartered in Kenilworth, New Jersey.
126 East Lincoln Avenue · Rahway, NJ 07065 · US
| Date | Time | Est | Rptd | Surp | Base | Gap% | D1% | D2% | D3% | D4% | D5% | Guide ▲★ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Apr 30, 2026 | BMO | -1.47 | -1.28 | +12.9% | 110.95 | -1.5% | -1.6% | +2.7% | +0.8% | +0.0% | +0.4% | — |
| Feb 3, 2026 | BMO | 2.01 | 2.04 | +1.5% | 113.37 | -1.5% | +2.2% | +2.1% | +1.2% | +1.8% | -3.5% | — |
| Oct 30, 2025 | BMO | 2.36 | 2.58 | +9.3% | 86.58 | -2.3% | -0.3% | -0.3% | -4.1% | +1.7% | +0.6% | — |
| Jul 29, 2025 | BMO | 2.03 | 2.13 | +4.9% | 84.06 | -5.0% | -1.7% | -1.1% | -4.4% | +1.5% | +0.7% | — |
| Apr 24, 2025 | BMO | 2.13 | 2.22 | +4.2% | 78.69 | -0.5% | +1.5% | +3.6% | +0.5% | +1.8% | +0.6% | — |
| Feb 4, 2025 | BMO | 1.85 | 1.72 | -7.0% | 99.79 | -10.8% | -9.1% | -1.2% | -1.8% | -0.9% | -1.0% | — |
| Oct 31, 2024 | BMO | 1.50 | 1.57 | +4.7% | 104.83 | -3.7% | -2.4% | -0.4% | -0.0% | -0.2% | -0.9% | — |
| Jul 30, 2024 | BMO | 2.15 | 2.28 | +6.0% | 127.78 | -3.4% | -9.8% | -1.8% | +0.6% | +1.2% | -2.5% | — |
| Apr 25, 2024 | BMO | 1.88 | 2.07 | +10.1% | 127.00 | +2.1% | +2.9% | +0.4% | -0.8% | -0.7% | -0.3% | — |
| Feb 1, 2024 | BMO | -0.09 | 0.03 | +133.3% | 120.78 | +2.4% | +4.6% | +0.0% | -0.2% | +0.6% | +0.5% | — |
| Oct 26, 2023 | BMO | 1.95 | 2.13 | +9.2% | 103.63 | -0.5% | +1.9% | -2.6% | -0.1% | +0.0% | +0.1% | — |
| Aug 1, 2023 | BMO | -2.17 | -2.06 | +5.1% | 106.65 | +2.8% | -1.3% | +0.4% | +0.0% | -0.7% | +1.0% | — |
| Date | Firm | Action | Grade | Target | Base | Open | Gap% | D1% | D2% | D3% | D4% | D5% |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| May 6 | Citigroup | Reiterates | Neutral | $125 | $113.15 | $113.15 | +0.0% | +0.4% | -1.1% | -0.8% | — | — |
| May 1 | Wells Fargo | Maintains | Overweight → Overweight | — | $109.18 | $112.33 | +2.9% | +2.7% | +0.8% | +0.0% | +0.4% | -1.1% |
| Apr 13 | UBS | Maintains | Buy → Buy | — | $121.42 | $121.03 | -0.3% | -1.0% | -0.2% | -1.7% | -2.1% | +3.1% |
| Apr 6 | JP Morgan | Maintains | Overweight → Overweight | — | $120.87 | $120.41 | -0.4% | -0.0% | -1.3% | +3.3% | -0.4% | -1.0% |
| Mar 30 | RBC Capital | Maintains | Outperform → Outperform | — | $119.63 | $120.57 | +0.8% | -1.3% | +1.9% | +0.5% | +0.0% | -0.0% |
| Mar 20 | Citigroup | Maintains | Neutral → Neutral | — | $114.20 | $114.25 | +0.0% | -0.0% | +1.3% | +0.6% | +2.6% | -0.4% |
| Mar 12 | Wells Fargo | Maintains | Overweight → Overweight | — | $116.21 | $115.47 | -0.6% | -0.3% | -0.3% | -0.2% | +0.4% | -1.2% |
| Feb 9 | Freedom Broker | Maintains | Hold → Hold | — | $121.93 | $121.41 | -0.4% | -3.5% | -0.4% | +1.8% | -0.0% | +1.8% |
| Feb 6 | Guggenheim | Maintains | Buy → Buy | — | $119.75 | $120.76 | +0.8% | +1.8% | -3.5% | -0.4% | +1.8% | -0.0% |
| Feb 4 | Cantor Fitzgerald | Maintains | Neutral → Neutral | — | $115.84 | $116.90 | +0.9% | +2.1% | +1.2% | +1.8% | -3.5% | -0.4% |
| Feb 4 | Citigroup | Maintains | Neutral → Neutral | — | $115.84 | $116.90 | +0.9% | +2.1% | +1.2% | +1.8% | -3.5% | -0.4% |
| Feb 4 | Wells Fargo | Maintains | Overweight → Overweight | — | $115.84 | $116.90 | +0.9% | +2.1% | +1.2% | +1.8% | -3.5% | -0.4% |
| Jan 27 | Citigroup | Maintains | Neutral → Neutral | — | $107.40 | $107.50 | +0.1% | +0.5% | -0.9% | +1.3% | +1.8% | +2.8% |
| Jan 20 | TD Cowen | Maintains | Hold → Hold | — | $108.83 | $108.11 | -0.7% | +0.6% | +1.5% | -1.7% | -0.9% | -0.7% |
| Jan 8 | Wolfe Research | Upgrade | Peer Perform → Outperform | — | $108.60 | $110.61 | +1.9% | +2.2% | -0.4% | -1.2% | -0.9% | +2.5% |
| Jan 7 | Citigroup | Maintains | Neutral → Neutral | — | $108.87 | $109.51 | +0.6% | -0.2% | +2.2% | -0.4% | -1.2% | -0.9% |
| Jan 7 | UBS | Maintains | Buy → Buy | — | $108.87 | $109.51 | +0.6% | -0.2% | +2.2% | -0.4% | -1.2% | -0.9% |
| Dec 18 | BMO Capital | Upgrade | Market Perform → Outperform | — | $99.18 | $99.27 | +0.1% | +1.5% | +0.4% | +3.6% | +0.3% | +1.3% |
| Dec 15 | BofA Securities | Maintains | Buy → Buy | — | $100.30 | $99.99 | -0.3% | -0.0% | -2.0% | +0.9% | +1.5% | +0.4% |
| Dec 12 | Morgan Stanley | Maintains | Equal Weight → Equal Weight | — | $99.01 | $98.96 | -0.1% | +1.3% | -0.0% | -2.0% | +0.9% | +1.5% |
| Dec 4 | Scotiabank | Maintains | Sector Outperform → Sector Outperform | — | $102.27 | $102.10 | -0.2% | -1.3% | -1.2% | -0.8% | -2.1% | +0.8% |
| Dec 2 | Goldman Sachs | Maintains | Buy → Buy | — | $101.83 | $101.53 | -0.3% | -0.8% | +1.2% | -1.3% | -1.2% | -0.8% |
| Nov 24 | Wells Fargo | Upgrade | Equal Weight → Overweight | — | $97.76 | $99.12 | +1.4% | +2.7% | +5.2% | -1.0% | +0.2% | -2.9% |
| Nov 18 | Deutsche Bank | Maintains | Hold → Hold | — | $92.86 | $94.11 | +1.3% | +3.8% | -1.4% | -0.1% | +2.9% | +2.7% |
| Nov 3 | Morgan Stanley | Maintains | Equal Weight → Equal Weight | — | $85.98 | $85.77 | -0.2% | -4.1% | +1.7% | +0.6% | +1.6% | +0.6% |
| Sep 17 | Berenberg | Downgrade | Buy → Hold | — | $81.09 | $80.98 | -0.1% | +0.1% | +0.5% | -0.0% | -1.4% | -0.5% |
| Jul 30 | Wells Fargo | Maintains | Equal Weight → Equal Weight | — | $82.63 | $82.91 | +0.3% | -1.1% | -4.4% | +1.5% | +0.7% | +1.2% |
| Jul 10 | Morgan Stanley | Maintains | Equal Weight → Equal Weight | — | $83.71 | $83.64 | -0.1% | +0.4% | -0.8% | +0.4% | -2.6% | +1.1% |
| May 14 | Citigroup | Downgrade | Buy → Neutral | — | $76.63 | $77.46 | +1.1% | -4.1% | +1.8% | +1.7% | +1.5% | +1.0% |
| Apr 17 | Guggenheim | Maintains | Buy → Buy | — | $76.46 | $76.89 | +0.6% | +2.0% | -0.2% | +1.4% | -0.4% | +1.5% |
| Feb 18 | Deutsche Bank | Downgrade | Buy → Hold | — | $83.01 | $81.13 | -2.3% | +0.3% | +2.8% | +2.4% | +2.1% | +2.0% |
| Feb 12 | Guggenheim | Maintains | Buy → Buy | — | $86.54 | $86.07 | -0.5% | -1.0% | -1.5% | -1.7% | +0.3% | +2.8% |
| Feb 5 | BofA Securities | Maintains | Buy → Buy | — | $90.74 | $90.39 | -0.4% | -1.2% | -1.8% | -0.9% | -1.0% | +0.2% |
| Feb 5 | BMO Capital | Maintains | Market Perform → Market Perform | — | $90.74 | $90.39 | -0.4% | -1.2% | -1.8% | -0.9% | -1.0% | +0.2% |
| Feb 5 | Morgan Stanley | Maintains | Equal Weight → Equal Weight | — | $90.74 | $90.39 | -0.4% | -1.2% | -1.8% | -0.9% | -1.0% | +0.2% |
| Feb 5 | Citigroup | Maintains | Buy → Buy | — | $90.74 | $90.39 | -0.4% | -1.2% | -1.8% | -0.9% | -1.0% | +0.2% |
| Jan 28 | Citigroup | Maintains | Buy → Buy | — | $97.94 | $97.35 | -0.6% | -0.5% | +0.9% | +0.7% | -0.1% | +1.0% |
| Jan 21 | Morgan Stanley | Maintains | Equal Weight → Equal Weight | — | $97.92 | $98.08 | +0.2% | -1.7% | -0.6% | +1.0% | -1.1% | +2.5% |
| Jan 17 | Guggenheim | Maintains | Buy → Buy | — | $100.70 | $100.47 | -0.2% | -2.8% | -1.7% | -0.6% | +1.0% | -1.1% |
| Jan 13 | Leerink Partners | Maintains | Outperform → Outperform | — | $99.25 | $99.46 | +0.2% | +1.7% | -1.3% | +0.4% | +0.6% | -2.8% |
| Jan 8 | Truist | Downgrade | Buy → Hold | — | $101.02 | $100.70 | -0.3% | -1.2% | -0.6% | +1.7% | -1.3% | +0.4% |
| Jan 8 | UBS | Maintains | Buy → Buy | — | $101.02 | $100.70 | -0.3% | -1.2% | -0.6% | +1.7% | -1.3% | +0.4% |
| Dec 20 | BMO Capital | Downgrade | Outperform → Market Perform | — | $99.52 | $98.83 | -0.7% | -1.5% | +1.3% | +0.1% | +0.4% | -0.2% |
| Nov 7 | Truist | Maintains | Buy → Buy | — | $100.73 | $101.44 | +0.7% | +0.4% | +1.7% | -2.1% | -2.1% | -0.1% |
| Nov 6 | Guggenheim | Maintains | Buy → Buy | — | $101.65 | $103.18 | +1.5% | -0.9% | +0.4% | +1.7% | -2.1% | -2.1% |
| Nov 1 | BMO Capital | Maintains | Outperform → Outperform | — | $102.32 | $101.78 | -0.5% | -0.4% | -0.0% | -0.2% | -0.9% | +0.4% |
| Nov 1 | Wells Fargo | Maintains | Equal Weight → Equal Weight | — | $102.32 | $101.78 | -0.5% | -0.4% | -0.0% | -0.2% | -0.9% | +0.4% |
| Nov 1 | Morgan Stanley | Maintains | Equal Weight → Equal Weight | — | $102.32 | $101.78 | -0.5% | -0.4% | -0.0% | -0.2% | -0.9% | +0.4% |
| Oct 25 | Citigroup | Maintains | Buy → Buy | — | $105.88 | $106.49 | +0.6% | -1.8% | +0.2% | -0.5% | +1.1% | -2.4% |
| Oct 9 | UBS | Maintains | Buy → Buy | — | $108.52 | $108.41 | -0.1% | +1.6% | -0.8% | +0.3% | -0.0% | +1.7% |
No insider trades available.
SC TO-T/A
! Medium
Terns Pharmaceuticals, Inc. -- Tender Offer Amendment
Merck's tender offer to acquire Terns Pharmaceuticals at $53 per share represents a significant deal combining Merck's scale with Terns' drug development capabilities.
May 5
SC TO-T
!!! Very High
Terns Pharmaceuticals, Inc. -- Tender Offer
Merck is acquiring Terns Pharmaceuticals for $53 per share in a tender offer, gaining access to Terns' pipeline of metabolic disease treatments and expanding its pharmaceutical portfolio.
Apr 24
SC TO-T
!!! Very High
Unknown — Tender Offer
Merck's tender offer for Tern Pharmaceuticals signals acquisition intent, potentially indicating confidence in Tern's pipeline value and providing Tern shareholders with liquidity while offering Merck near-term asset diversification.
Apr 7
8-K
Merck & Co., Inc. -- 8-K Filing
Merck projects 2026 sales of $65.5-$67.0 billion and non-GAAP EPS of $5.00-$5.15, with a $3.65-per-share charge from its Cidara acquisition, signaling measured growth expectations.
Feb 3
Data updated apr 26, 2026 1:13pm
· Source: massive.com